Interest of Circulating Tumor DNA in Digestive and Gynecologic/Breast Cancer

Launched by POITIERS UNIVERSITY HOSPITAL · Aug 25, 2020

Keywords

ClinConnect Summary

The ADIGYN study is focused on understanding the role of circulating tumor DNA (ctDNA) and exosomes in patients with digestive, gynecological, and breast cancers. ctDNA is a type of genetic material that comes from tumors and can be found in the blood. This study aims to see how well ctDNA and exosomes can help doctors diagnose cancer, predict how patients will respond to treatments, and monitor their progress over time. By looking at ctDNA before, during, and after treatment, researchers hope to gain valuable insights that could improve cancer care.

To participate in this study, patients must have a confirmed or suspected diagnosis of digestive or gynecological/breast cancer and need oncological treatment, such as chemotherapy or immunotherapy. Eligible participants should be adults who can understand the study information and provide consent. Throughout the trial, participants will undergo blood tests to analyze ctDNA and exosomes, which will help researchers gather important information about their cancer and treatment responses. This study is currently recruiting participants and aims to gather data that could significantly enhance cancer treatment strategies in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Digestive or gynecological / breast cancer proven or suspected, requiring oncological treatment (chemotherapy or immunotherapy)
• • Major patient
• • Patients benefiting from a Social Security scheme or benefiting through the intermediary of a third party
• • Information note and collection of non-opposition after clear and fair information about the study
• Exclusion Criteria:
• • Linguistic or psychological refusal or inability to understand and / or sign the information and no-objection note
• • History of a cancer other than that allowing inclusion in the 5 years preceding inclusion